Evolus Inc.

13.58-0.3300-2.37%Vol 417.20K1Y Perf 240.40%
Apr 9th, 2021 16:00 DELAYED
BID12.97 ASK14.52
Open13.83 Previous Close13.91
Pre-Market- After-Market-
 - -  - -%
Target Price
15.00 
Analyst Rating
Strong Buy 1.25
Potential %
10.46 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     29.73
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap593.89M 
Earnings Rating
Neutral
Price Range Ratio 52W %
73.85 
Earnings Date
10th May 2021

Today's Price Range

13.2814.43

52W Range

2.8517.38

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
7.86%
1 Month
16.07%
3 Months
220.28%
6 Months
199.12%
1 Year
240.40%
3 Years
51.22%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EOLS13.58-0.3300-2.37
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
0.70
0.70
0.80
3.92
-14.50
Leverage Ratio -16.50
ProfitabilityValueIndustryS&P 500US Markets
67.60
-102.10
-89.00
-
-
RevenueValueIndustryS&P 500US Markets
46.04M
1.05
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.33-0.81-145.45
Q03 2020-0.50-0.3432.00
Q02 2020-0.84-0.6325.00
Q01 2020-0.72-0.5918.06
Q04 2019-0.85-0.4744.71
Q03 2019-1.33-0.9826.32
Q02 2019-0.96-1.37-42.71
Q01 2019-0.82-0.93-13.41
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.3819.15Positive
6/2021 QR-0.1441.67Positive
12/2021 FY-0.95-7.95Negative
12/2022 FY-0.46-6.98Negative
Next Report Date10th May 2021
Estimated EPS Next Report-0.38
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume417.20K
Shares Outstanding43.73M
Trades Count4.82K
Dollar Volume14.49M
Avg. Volume1.55M
Avg. Weekly Volume599.50K
Avg. Monthly Volume1.20M
Avg. Quarterly Volume1.61M

Evolus Inc. (NASDAQ: EOLS) stock closed at 13.58 per share at the end of the most recent trading day (a -2.37% change compared to the prior day closing price) with a volume of 420.35K shares and market capitalization of 593.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 125 people. Evolus Inc. CEO is David Moatazedi.

The one-year performance of Evolus Inc. stock is 240.4%, while year-to-date (YTD) performance is 304.17%. EOLS stock has a five-year performance of %. Its 52-week range is between 2.85 and 17.38, which gives EOLS stock a 52-week price range ratio of 73.85%

Evolus Inc. currently has a PE ratio of -2.60, a price-to-book (PB) ratio of 15.88, a price-to-sale (PS) ratio of 11.96, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.24%, a ROC of -42.11% and a ROE of -2 406.17%. The company’s profit margin is -%, its EBITDA margin is -89.00%, and its revenue ttm is $46.04 Million , which makes it $1.05 revenue per share.

Of the last four earnings reports from Evolus Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Evolus Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Evolus Inc. is Strong Buy (1.25), with a target price of $15, which is +10.46% compared to the current price. The earnings rating for Evolus Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evolus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evolus Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 47.97, ATR14 : 1.51, CCI20 : 55.40, Chaikin Money Flow : 0.01, MACD : 1.53, Money Flow Index : 86.08, ROC : 13.65, RSI : 62.53, STOCH (14,3) : 69.91, STOCH RSI : 0.27, UO : 52.81, Williams %R : -30.09), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evolus Inc. in the last 12-months were: David Moatazedi (Sold 8 310 shares of value $61 993 ), Lauren P. Silvernail (Sold 2 699 shares of value $20 135 ), Michael M. Jafar (Sold 2 699 shares of value $20 135 ), Rui Avelar (Sold 2 699 shares of value $20 135 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (77.78 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (12.50 %)
1 (11.11 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
1 (11.11 %)
1 (11.11 %)
Summary RatingStrong Buy
1.25
Moderate Buy
1.67
Moderate Buy
1.67

Evolus Inc.

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines.

CEO: David Moatazedi

Telephone: +1 949 284-4555

Address: 520 Newport Center Drive, Newport Beach 92660, CA, US

Number of employees: 125

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

62%38%

Bearish Bullish

52%48%

News

Stocktwits